Eli Lilly (LLY) earnings Q1 2024

[Pelican Press 0]

Eli Lilly (LLY) earnings Q1 2024

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020. 

Mike Blake | Reuters

Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes ***** Mounjaro and newly launched weight loss treatment Zepbound.

The drugmaker now expects full-year adjusted earnings of $13.50 to $14.00 per share, up from a previous guidance of $12.20 to $12.70 per share. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range.

Analysts surveyed by LSEG expected full-year adjusted earnings of $12.50 per share and sales of $41.44 billion. 

The results and guidance raise reflect Zepbound’s first full quarter on the U.S. market after winning approval from regulators in early November. The ***** reported $517.4 million in sales for the first quarter, even as most doses of the ***** slipped into shortages in the U.S. that are expected to last through June.

Analysts say the weekly injection could post more than a billion dollars in sales in its first year on the market and potentially become the biggest ***** of all time.

Here’s what Eli Lilly reported for the

This is the hidden content, please

• Sign In
• or
• Sign Up

compared with what Wall Street was expecting, based on a survey of analysts by LSEG: 

• Earnings per share: $2.58 adjusted vs. $2.46 expected
• Revenue: $8.77 billion vs. $8.92 billion expected

Eli Lilly posted a net income of $2.24 billion, or $2.48 a share, for the first quarter. That compares with a profit of $1.34 billion, or $1.49 a share, a year earlier. 

Excluding one-time items associated with the value of intangible assets, among other adjustments, the company posted a per-share profit of $2.58 for the first quarter of 2024.

The pharmaceutical giant booked first-quarter revenue of $8.77 billion, up 26% year over year.

In February, Eli Lilly said it expects revenue growth to accelerate in the second half of the year, which will be consistent with the increased availability of incretin ***** doses. Incretin drugs are treatments such as Mounjaro and Zepbound, which mimic hormones produced in the gut to suppress a person’s appetite and regulate their blood sugar.

Shares of Eli Lilly jumped almost 8% in premarket trading Tuesday. They’re up 26% this year after jumping almost 60% in 2023 due to the insatiable demand for the company’s weight loss and diabetes drugs. That’s despite their hefty price tags, spotty insurance coverage and intermittent supply shortages. 

With a market cap of about $700 billion, Eli Lilly is the largest pharmaceutical company based in the U.S. 

This story is developing. Please check back for updates.

This is the hidden content, please

• Sign In
• or
• Sign Up

Business,Biotechnology,Biotech and Pharmaceuticals,Pharmaceuticals,Health care industry,Earnings,Breaking news,Eli Lilly and Co,******* States,business news
#Eli #Lilly #LLY #earnings

This is the hidden content, please

• Sign In
• or
• Sign Up